Literature DB >> 12825454

The monoamine neurotransmitter transporters: structure, conformational changes and molecular gating.

L Norregaard1, U Gether.   

Abstract

Monoamine transporters are primary targets for the action of many psychoactive compounds including the most commonly used antidepressants and widely abused drugs, such as cocaine and amphetamine. Consequently, these transporters are the focus of continuous intensive research. Over the last couple of years, these efforts have resulted in significant progress both in our understanding of their role in drug abuse mechanisms and of the structural basis that underlies their capability as transporters to translocate their substrate across the plasma membrane. The aim of this review is to describe both the current awareness regarding the structural organization of the monoamine neurotransmitter transporters as well as the molecular mechanisms responsible for function, with specific emphasis on conformational changes and putative gating mechanisms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12825454

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN: 1367-6733


  12 in total

1.  Site-directed mutations near transmembrane domain 1 alter conformation and function of norepinephrine and dopamine transporters.

Authors:  Bipasha Guptaroy; Rheaclare Fraser; Aalisha Desai; Minjia Zhang; Margaret E Gnegy
Journal:  Mol Pharmacol       Date:  2010-12-13       Impact factor: 4.436

2.  Dopamine transporter down-regulation following repeated cocaine: implications for 3,4-methylenedioxymethamphetamine-induced acute effects and long-term neurotoxicity in mice.

Authors:  I Peraile; E Torres; A Mayado; M Izco; A Lopez-Jimenez; J A Lopez-Moreno; M I Colado; E O'Shea
Journal:  Br J Pharmacol       Date:  2009-12-10       Impact factor: 8.739

3.  Surface targeting of the dopamine transporter involves discrete epitopes in the distal C terminus but does not require canonical PDZ domain interactions.

Authors:  Christian Bjerggaard; Jacob U Fog; Hanne Hastrup; Kenneth Madsen; Claus J Loland; Jonathan A Javitch; Ulrik Gether
Journal:  J Neurosci       Date:  2004-08-04       Impact factor: 6.167

4.  DNA methylation and expression profiles of the brain-derived neurotrophic factor (BDNF) and dopamine transporter (DAT1) genes in patients with schizophrenia.

Authors:  Dor Mohammad Kordi-Tamandani; Roya Sahranavard; Adam Torkamanzehi
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

5.  Mutational analysis of the high-affinity zinc binding site validates a refined human dopamine transporter homology model.

Authors:  Thomas Stockner; Therese R Montgomery; Oliver Kudlacek; Rene Weissensteiner; Gerhard F Ecker; Michael Freissmuth; Harald H Sitte
Journal:  PLoS Comput Biol       Date:  2013-02-21       Impact factor: 4.475

6.  A direct interaction of cholesterol with the dopamine transporter prevents its out-to-inward transition.

Authors:  Talia Zeppelin; Lucy Kate Ladefoged; Steffen Sinning; Xavier Periole; Birgit Schiøtt
Journal:  PLoS Comput Biol       Date:  2018-01-12       Impact factor: 4.475

7.  Effect of palmitoylation on the dimer formation of the human dopamine transporter.

Authors:  Talia Zeppelin; Kasper B Pedersen; Nils A Berglund; Xavier Periole; Birgit Schiøtt
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

8.  Substrate-dependent proton antiport in neurotransmitter:sodium symporters.

Authors:  Yongfang Zhao; Matthias Quick; Lei Shi; Ernest L Mehler; Harel Weinstein; Jonathan A Javitch
Journal:  Nat Chem Biol       Date:  2009-12-27       Impact factor: 15.040

9.  Regulation of dopamine transporter activity by carboxypeptidase E.

Authors:  Heping Zhang; Shupeng Li; Min Wang; Brian Vukusic; Zdenek B Pristupa; Fang Liu
Journal:  Mol Brain       Date:  2009-05-06       Impact factor: 4.041

10.  Living without DAT: Loss and compensation of the dopamine transporter gene in sauropsids (birds and reptiles).

Authors:  P V Lovell; B Kasimi; J Carleton; T A Velho; C V Mello
Journal:  Sci Rep       Date:  2015-09-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.